UBS Group’s Biodexa Pharmaceuticals BDRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73 | Hold |
25
| – | – | ﹤0.01% | 10147 |
|
|
2026
Q1 | $78 | Sell |
25
-395
| -94% | -$2.78K | ﹤0.01% | 10150 |
|
|
2025
Q4 | $4.77K | Sell |
420
-965
| -70% | -$27.5K | ﹤0.01% | 8783 |
|
|
2025
Q3 | $46.1K | Buy |
1,385
+1,345
| +3,363% | +$48.3K | ﹤0.01% | 7626 |
|
|
2025
Q2 | $1.72K | Sell |
40
-337
| -89% | -$21.5K | ﹤0.01% | 9575 |
|
|
2025
Q1 | $24.9K | Buy |
377
+236
| +167% | +$41.3K | ﹤0.01% | 8079 |
|
|
2024
Q4 | $28.5K | Sell |
141
-63
| -31% | -$16.5K | ﹤0.01% | 7640 |
|
|
2024
Q3 | $72K | Buy |
204
+196
| +2,450% | +$150K | ﹤0.01% | 6581 |
|
|
2024
Q2 | $8.96K | Buy |
8
+6
| +300% | +$7.86K | ﹤0.01% | 7769 |
|
|
2024
Q1 | $3.95K | Buy |
+2
| New | +$3.96K | ﹤0.01% | 7679 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 8264 |
|
|
2023
Q3 | – | Sell |
-1
| Closed | -$6.89K | – | 8557 |
|
|
2023
Q2 | $9.81K | Buy |
+1
| New | +$17.9K | ﹤0.01% | 7163 |
|
|
2023
Q1 | – | Hold |
0
| – | -$123 | – | 9606 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 10375 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 9000 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 9508 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 9272 |
|
|
2021
Q3 | – | Hold |
0
| – | -$16K | – | 9528 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 7562 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 6491 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 8080 |
|
|
2020
Q3 | – | Hold |
0
| – | -$42K | – | 7977 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6008 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7274 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7816 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7991 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 7522 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7728 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7614 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7394 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7532 |
|
|
2018
Q1 | – | Hold |
0
| – | -$1K | – | 7804 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7693 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7299 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7664 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6881 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7315 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7116 |
|
|
2016
Q1 | – | Hold |
0
| – | -$12K | – | 7640 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7161 |
|
Other funds holding BDRX
GI
APW
SS
HHCP
CIAM
UBS Group's BDRX Position: Q2 2026 in Review
UBS Group held its Biodexa Pharmaceuticals (BDRX) position steady in Q2 2026 at 25 shares worth $73. The position accounts for ﹤0.01% of the portfolio, ranked #10147.
UBS Group first reported a position in BDRX in Q2 2023 and has held it in 11 quarters since. The position peaked at $72K in Q3 2024. 7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.
- UBS Group held 25 shares of Biodexa Pharmaceuticals worth $73 as of Q2 2026.
- UBS Group left its Biodexa Pharmaceuticals share count unchanged in Q2 2026.
- Biodexa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10147 holding.
- UBS Group first reported a position in Biodexa Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
- UBS Group's Biodexa Pharmaceuticals position peaked at $72K in Q3 2024.
- 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.